Drossapharm Ag

Jurg Lutz

Henning F Cierpka

Sufficiently high blood benzopyrone levels cannot be achieved on oral administration of benzopyrone. From the point of view of pharmacokinetics and chronic application, the use of benzopyrone as an ointment is not optimal because the blood levels thus achievable cannot be controlled. It has now surprisingly been found that benzopyrone in a particular formulation as part of a transdermal dermal therapeutic system (TDS), after application to the skin, is released to the skin in a constant manner as a function of time and over a longer period owing to the absorption of perspiration, and that constant therapeutically effective blood and tissue levels of benzopyrone are achieved in humans, which levels are a factor of 50 higher than those following the oral administration of the same doses of benzopyrone.

Growing community of inventors

Binningen, Switzerland

Jurg Lutz